About Karyopharm Therapeutics Inc.
https://www.karyopharm.comKaryopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.
CEO
Richard A. Paulson
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-02-26 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
RBC Capital
Outperform
Baird
Outperform
Piper Sandler
Overweight
Barclays
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:4.17M
Value:$29.98M
DELPHI MANAGEMENT PARTNERS VIII, L.L.C.
Shares:2.26M
Value:$16.27M
BLACKROCK FUND ADVISORS
Shares:1.38M
Value:$9.9M
Summary
Showing Top 3 of 86
About Karyopharm Therapeutics Inc.
https://www.karyopharm.comKaryopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $44.04M ▲ | $57.15M ▼ | $-33.13M ▲ | -75.21% ▲ | $-3.82 ▲ | $-22.56M ▲ |
| Q2-2025 | $37.93M ▲ | $61.27M ▼ | $-37.25M ▼ | -98.22% ▼ | $-4.32 ▼ | $-25.91M ▼ |
| Q1-2025 | $30.02M ▼ | $61.97M ▲ | $-23.46M ▲ | -78.17% ▲ | $-2.77 ▲ | $-12.35M ▲ |
| Q4-2024 | $30.54M ▼ | $60.49M ▼ | $-30.78M ▲ | -100.78% ▼ | $-3.67 ▲ | $-19.6M ▲ |
| Q3-2024 | $38.78M | $63.77M | $-32.07M | -82.7% | $-3.85 | $-20.58M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $45.88M ▼ | $96.23M ▼ | $365.49M ▲ | $-269.26M ▼ |
| Q2-2025 | $51.7M ▼ | $104.88M ▼ | $343.81M ▲ | $-238.93M ▼ |
| Q1-2025 | $69.94M ▼ | $127.71M ▼ | $333.6M ▼ | $-205.88M ▼ |
| Q4-2024 | $108.71M ▼ | $164.42M ▼ | $350.44M ▲ | $-186.02M ▼ |
| Q3-2024 | $133.53M | $189.48M | $349.12M | $-159.65M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-33.13M ▲ | $0 ▲ | $0 ▼ | $0 ▼ | $-39.08M ▼ | $0 ▲ |
| Q2-2025 | $-37.25M ▼ | $-18.7M ▲ | $18.29M ▲ | $356K ▲ | $-48K ▲ | $-18.7M ▲ |
| Q1-2025 | $-23.46M ▲ | $-38.98M ▼ | $15.29M ▲ | $0 ▼ | $-23.69M ▼ | $-38.98M ▼ |
| Q4-2024 | $-30.78M ▲ | $-25.81M ▼ | $14.8M ▲ | $680K ▲ | $-10.35M ▲ | $-25.76M ▼ |
| Q3-2024 | $-32.07M | $-19.45M | $7.47M | $0 | $-11.94M | $-19.45M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Health Care Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 License and Service | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Other Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Richard A. Paulson
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-02-26 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
RBC Capital
Outperform
Baird
Outperform
Piper Sandler
Overweight
Barclays
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:4.17M
Value:$29.98M
DELPHI MANAGEMENT PARTNERS VIII, L.L.C.
Shares:2.26M
Value:$16.27M
BLACKROCK FUND ADVISORS
Shares:1.38M
Value:$9.9M
Summary
Showing Top 3 of 86